Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1997-12-17
|
pubmed:abstractText |
Neutropenia is one of the risk factors for severe therapy-related morbidity in childhood malignancies. We have studied the potential of GM-CSF to shorten the neutropenic period after normal-dose chemotherapy in children who were treated for solid tumors. Patients with osteosarcomas, with Ewing sarcomas, or with rhabdomyosarcomas received 10 daily subcutaneous doses GM-CSF (Leucomax, 5 micrograms/kg) after a course of normal-dose chemotherapy in an open-label study. Because these patients were treated with different combinations of chemotherapeutic agents, they were randomized before each pair of identical courses of chemotherapy to receive GM-CSF after the first or after the second course. Fourteen such combinations could be evaluated in eight patients. The results show that GM-CSF significantly reduced the mean duration of the chemotherapy-induced neutropenia (mean reduction +/- SEM in days: 2.2 +/- 0.6, P = .003). There was no significant difference between the mean number of days with fever in either group. GM-CSF was well tolerated by all patients. We conclude that GM-CSF reduced the mean neutropenic period in children with solid tumors who were treated with standard-dose chemotherapy.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0888-0018
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
539-45
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9383806-Adolescent,
pubmed-meshheading:9383806-Antineoplastic Agents,
pubmed-meshheading:9383806-Child,
pubmed-meshheading:9383806-Child, Preschool,
pubmed-meshheading:9383806-Female,
pubmed-meshheading:9383806-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:9383806-Humans,
pubmed-meshheading:9383806-Infant,
pubmed-meshheading:9383806-Male,
pubmed-meshheading:9383806-Neoplasms,
pubmed-meshheading:9383806-Neutropenia,
pubmed-meshheading:9383806-Osteosarcoma,
pubmed-meshheading:9383806-Rhabdomyosarcoma,
pubmed-meshheading:9383806-Sarcoma, Ewing
|
pubmed:articleTitle |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors.
|
pubmed:affiliation |
Academic Medical Center, University of Amsterdam, Emma Kinderziekenhuis AMC, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|